Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent form~* Male or female of aged 50 years or older~* Typical AMD and PCV patients~* BCVA of 24 letters or over~Exclusion Criteria:~* Total lesion area of \>12 DA or \>30.5 mm2~* The existence of subretinal hemorrhage area constituting ≥50% of total lesion area~* The existence of scar or fibrosis area constituting ≥50% of total lesion area~* The existence of RPE tear~* Prior treatment for wet AMD~* History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD~* The pregnant or lactating woman

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intraviteal Ranibizumab 0.5mg (Type: EXPERIMENTAL): Intraviteal Ranibizumab 0.5mg

Based on this trial design, predict the completion outcome and termination type (if applicable).